Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 20, 2010 - Issue 11
Submit an article Journal homepage
406
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Update on lymphocyte specific kinase inhibitors: a patent survey

Matthew W Martin Amgen, Inc., Department of Medicinal Chemistry, 360 Binney Street, Cambridge, Massachusetts 02142, USA +1 617 444 5013; +1 617 577 9839; [email protected]
, PhD &
Michelle R Machacek Merck Research Labs, Department of Chemistry, 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA +1 617 992 2059; +1 617 992 2406; [email protected]
, PhD
Pages 1573-1593 | Published online: 10 Sep 2010

Bibliography

  • Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol 2000;12:242-9
  • Bolen JB, Brugge JS. Leukocyte protein tyrosine kinases: potential targets for drug discovery. Annu Rev Immunol 1997;15:371-404
  • Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev 1996;10:1845-57
  • Marth JD, Lewis DB, Cooke MP, Lymphocyte activation provokes modification of a lymphocyte specific protein tyrosine kinase (p56lck). J Immunol 1989;142:2430-7
  • Groves T, Smiley P, Cooke MP, Fyn can partially substitute for Lck in T lymphocyte development. Immunity 1996;5:417-28
  • Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000
  • Salmond RJ, Filby A, Qureshi I, T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009;228:9-22
  • Molina TJ, Kishihara K, Siderovskid DP, Profound block in thymocyte development in mice lacking p56lck. Nature 1992;357:161-4
  • Levin SD, Anderson SJ, Forbush KA, Perlmutter RM. A dominant-negative transgene defines a role for p56lck in thymopoiesis. EMBO J 1993;12:1671-80
  • Seddon B, Zamoyska R. TCR signals mediated by Src family kinases are essential for the survival of naive T cells. J Immunol 2002;169:2997-3005
  • Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992;70:585-93
  • Goldman FD, Ballas ZK, Schutte BC, Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998;102:421-9
  • Hubert P, Bergeron F, Ferreirea V, Defective p56lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000;12:449-57
  • Meyn MA III, Smithgall TE. Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem 2008;8:628-37
  • Bhagwat S. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal 2009;5:107-15
  • Dowden J, Ward SG. Inhibitors of p56lck: assessing their potential as tools for manipulating T-lymphocyte activation. Expert Opin Ther Patents 2001;11:295-306
  • Parang K, Sun G. Recent advances in the discovery of Src kinase inhibitors. Expert Opin Ther Patents 2005;15:1183-207
  • Zhu X, Kim JL, Newcomb JR, Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999;7:651-61
  • Yamaguchi H, Hendrickson WA. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996;388:484-9
  • Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595-602
  • Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602-9
  • Noble MEM, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5
  • Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64
  • DiMauro EF, Newcomb J, Nunes JJ, Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2006;49:5671-86
  • Zuccotto F, Ardini E, Casale E, Angiolini M. Through the “Gatekeeper Door”: exploiting the active kinase conformation. J Med Chem 2010;53:2681-94
  • Morphy R. Selectively nonselective kinase inhibition: strking the right balance. J Med Chem 2010;53:1413-37
  • Newton R, Holden N. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? BioDrugs 2003;17:113-29
  • Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptor. Nat Med 2003;9:669-76
  • Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosuppression. Expert Opin Ther Targets 2004;8:613-29
  • Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003;34:61-8
  • Pfizer, Inc. Preparation of 4-aminopyrazolo[3,4-d]pyrimidines and 4-aminopyrazolo[3,4-d]pyridines as tyrosine kinase inhibitors. US5593997; 1997
  • Hanke JH, Gardner JP, Dow RL, Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 1996;271(2):695-701
  • Arnold LD, Calderwood DJ, Dixon RW, Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck I. Bioorg Med Chem Lett 2000;10:2167-70
  • Burchat AF, Calderwood DJ, Hirst GC, Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck II. Bioorg Med Chem Lett 2000;10:2171-4
  • Calderwood DJ, Johnston DN, Munschauer R, Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Lck. Bioorg Med Chem Lett 2002;12:1683-6
  • Burchat AF, Calderwood DJ, Friedman MM, Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck–a selectivity insight. Bioorg Med Chem Lett 2002;12:1687-90
  • Abbott Laboratories. Method of treating transplant rejection. US20050008640; 2005
  • Borhani DW, Calderwood DJ, Friedman MM, A-420983: a potent, orally active inhibitor of Lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett 2004;14:2613-16
  • Burchat A, Borhani DW, Calderwood DJ, Discovery of A-770041, a Src-family selective orally active Lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett 2006;16:118-22
  • Stachlewitz RF, Hart MA, Bettencourt B, A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. J Pharm Exp Ther 2005;315:36-41
  • Abbott L, Betschmann P, Burchat A, Discovery of thienopyridines as Src-family selective Lck inhibitors. Bioorg Med Chem Lett 2007;17:1167-71
  • Abbott Laboratories. Thienopyridine kinase inibitors. US20050020619; 2005
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20050026944; 2005
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. WO05010009; 2005
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US2005043347; 2005
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US7202363; 2007
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20070155776; 2007
  • Abbott Laboratories. Thienopyridine and furopyridine kinase inhibitors. US20100069371; 2010
  • Dai Y, Guo Y, Frey RR, Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2005;48:6066-83
  • Heyman HR, Frey RR, Bousquet PF, Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett 2007;17:1246-9
  • Vertex Pharmaceuticals, Inc. Pyrrolo[3,2-c]pyridines useful as inhibitors of protein kinases. WO07095223; 2007
  • Vertex Pharmaceuticals, Inc. Pyrrolo[3,2-c]pyridines useful as inhibitors of protein kinases. US7659283; 2010
  • Amgen, Inc. Furanopyrimidines. WO06004658; 2006
  • DiMauro EF, Newcomb J, Nunes JJ, Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR. Bioorg Med Chem Lett 2007;17:2305-9
  • Manser E, Leung T, Salihuddin H, A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993;363:364-7
  • Xiao S-H, Farrelly E, Anzola J, An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1. Anal Biochem 2007;367:179-89
  • Amgen, Inc. Furanopyridine derivatives and methods of use. WO06130160; 2006
  • Amgen, Inc. Furanopyridine derivatives and methods of use. US7674907; 2010
  • Martin MW, Newcomb J, Nunes JJ, Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 2007;17:2299-304
  • Amgen, Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and Lck activity. WO06004703; 2006
  • Amgen, Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity. US7358250; 2008
  • Astra Zeneca AB. Quinazoline compounds with therapeutic use. US7223756; 2007
  • Astra Zeneca AB. Quinazoline compounds with therapeutic use. US20050009850; 2005
  • F. Hoffman-La Roche AG. Bicyclic nitrogen heterocycles. WO00024744; 2000
  • Kraker AJ, Hartl BG, Amam AM, Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol 2000;60:885-98
  • F. Hoffman-La Roche AG. Amino-substituted dihydropyrimido[4,5-d] pyrimidinone derivatives. US7091345; 2006
  • F. Hoffman-La Roche AG. Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents. WO06024487; 2006
  • F. Hoffman-La Roche AG. Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives. US7189732; 2007
  • F. Hoffman-La Roche AG. Novel dichloro-phenyl-pyrido[2,3-d]pyrimidine derivatives, their manufacture and use as pharmaceutical agents. WO05090344; 2005
  • F. Hoffman-La Roche AG. 6-(2-alkyl-phenyl)-pyrido[2,3-d]pyrimidines useful as protein kinase inhibitors. WO06032452; 2006
  • Amgen, Inc. Substituted heterocyclic compounds and methods of use. WO05042518; 2005
  • Martin MW, Newcomb J, Nunes JJ, Structure-based design of novel 2-Amino-6-phenylpyrimido[5′,4′:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2008;51:1637-48
  • Amgen, Inc. Substituted heterocyclic compounds and methods of use. WO05021551; 2005
  • Amgen, Inc. 2-Aminopyrimidine and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases. WO05009978; 2005
  • Martin MW, Newcomb J, Nunes JJ, Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem 2006;49:4981-91
  • Amgen, Inc. Substituted heterocyclic compounds and methods of use. US7442698; 2008
  • Amgen, Inc. Substituted heterocyclic compounds and methods of use. US7504396; 2009
  • Amgen, Inc. 2-Amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases. WO05009443; 2005
  • Amgen, Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators. WO07024680; 2007
  • IRM LLC. Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors. WO07005673; 2007
  • Zhang G, Ren, P, Gray NS, Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I. Bioorg Med Chem Lett 2008;18:5618-21
  • Zhang G, Ren, P, Gray NS, Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors: part II. Bioorg Med Chem Lett 2009;19:6691-5
  • Novartis Pharma GMBH. Pyrimidine urea derivatives as kinase inhibitors. WO06000420; 2006
  • Vertex Pharmaceuticals, Inc. Inhibitors of Src and Lck protein kinases. US20050049246; 2005
  • Vertex Pharmaceuticals, Inc. Inhibitors of C-Jun N-terminal kinases (JNK) and other protein kinases. US6949544; 2005
  • Vertex Pharmaceuticals, Inc. Inhibitors of C-Jun N-terminal kinases (JNK) and other protein kinases. US7084159; 2006
  • Hunt JA, Beresis RT, Goulet JL, Disubstituted pyrimidines as Lck inhibitors. Bioorg Med Chem Lett 2009;19:5440-3
  • Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases. US6844435; 2005
  • Snow RJ, Cardozo MG, Morwick TM, Discovery of 2-phenylamino-imidazo[4,5-h]isoquinolin-9-ones: a new class of inhibitors of Lck kinase. J Med Chem 2002;45:3394-405
  • Goldberg DR, Butz T, Cardozo MG, Optimization of 2-phenylaminoimidazo[4,5-h] isoquinolin-9-ones: orally active inhibitors of Lck kinase. J Med Chem 2003;46:1337-49
  • Bristol Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors. WO00062778; 2000
  • Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US6979694; 2005
  • Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7091223; 2006
  • Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7125875; 2006
  • Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7153856; 2006
  • Bristol Myers Squibb Co. Cyclic Protein Tyrosine Kinase Inhibitors. US7189854; 2007
  • Chen P, Norris D, Das J, Discovery of novel 2-(heteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinsae p56-Lck inhibitors. Bioorg Med Chem Lett 2004;14:6061-6
  • Das J, Chen P, Norris D, 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity studies toward the discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src Kinase Inhibitor. J Med Chem 2006;49:6819-32
  • IRM LLC. Benzothiazole derivatives and their use as protein tyrosine kinase inhibitors. WO08124393; 2008
  • Huang S, Liu Z, Tian SS, Discovery of 2-amino-6-carboxamidobenzothiazoles as potent Lck inhinitors. Bioorg Med Chem Lett 2008;18:2324-8
  • Das J, Moquin R, Lin J, Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56-Lck inhibitors. Bioorg Med Chem Lett 2003;13:2587-90
  • Taisho Pharmaceutical Co. Ltd. Pyrrole derivative. WO05123671; 2005
  • Takayama T, Umemiya H, Amada H, Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR. Bioorg Med Chem Lett 2010;20:108-11
  • Taisho Pharmaceutical Co. Ltd. Ring-fused pyrrole derivative. WO07026720; 2007
  • Takayama T, Umemiya H, Amada H, Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): structure, synthesis, and SAR. Bioorg Med Chem Lett 2010;20:112-16
  • Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. WO07117692; 2007
  • Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. US20090306155; 2009
  • Vertex Pharmaceuticals, Inc. Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases. US7589214; 2009
  • Novartis AG. Pyrazolo[1,5-a]pyrimidine derivatives and their therapeutic use. WO08037459; 2008
  • Novartis Institutes for Biomedical Research, Inc. Lck Inhibitors. US20100029636; 2010
  • Amgen, Inc. Aryl nitrogen-containing bicyclic compounds and methods of use. WO06039718; 2006
  • Amgen, Inc. Bis-aryl amide compounds and methods of use. WO07022380; 2007
  • DiMauro EF, Newcomb J, Nunes JJ, Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of Lck: synthesis, SAR, and inhibition of in vivo T-cell activation. J Med Chem 2008;51:1681-94
  • Deak HL, Newcomb JR, Nunes JJ, N-(3-(Phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR. Bioorg Med Chem Lett 2008;18:1172-6
  • Amgen, Inc. Heteroaryl-substituted alkyne compounds and methods of use. WO06044823; 2006
  • Cee VJ, Albrecht BK, Geuns-Meyer S, Alkynylpyrimidine Amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. J Med Chem 2007;50:627-40
  • Amgen, Inc. Compounds and methods of use. WO05070891; 2005
  • Amgen, Inc. Compounds and methods of use. US7435823; 2008
  • Harmange JC, Weiss MM, Germain J, Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem 2008;51:1649-67
  • Weiss MM, Harmange JC, Polverino AJ, Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J Med Chem 2008;51:1668-80
  • Bhagwat SS. MAP kinase inhibitors in inflammation and autoimmune disorders. Ann Rep Med Chem 2007;42:265-78
  • Dominguez C, Powers DA, Tamayo N. P38 MAP kinase inhibitors: Many are made, but few are chosen. Curr Opin Drug Disc Dev 2005; 8:421-30
  • Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:37-320
  • Stachlewitz R, Schwartz A, Bettencourt B, Toxicity of a selective inhibitor of Lck is due to inhibition of Lck and is not chemotype-related [poster 462]. Presented at the 44th Annual Meeting of the Society of Toxicology; March 2005; New Orleans, LA

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.